Market Cap ₹5796 Cr.
Stock P/E 146.6
P/B 4.9
Current Price ₹1416.1
Book Value ₹ 289.7
Face Value 10
52W High ₹1476
Dividend Yield 0.21%
52W Low ₹ 1005.1
Ami Organics Ltd engages in the R&D, manufacture, and sale of pharmaceutical intermediates in India. The enterprise offers about 450 pharma intermediates to be used in regulated and generic active pharmaceutical components for anti-retroviral, anti-inflammatory, anti-psychotic, anti-cancer, anti-parkinson, anti-depressant, and anti-coagulant packages, in addition to new chemical entities. It additionally offers preservatives, such as parabens and parabens formulations for use in cosmetics, animal meals, and personal care industries; and specialty chemicals for use in cosmetics, dyes, polymers, and agrochemicals. In addition, the company exports its products to approximately 25 nations worldwide. Ami Organics Ltd founded in 2004 and is based in Surat, India.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 144 | 131 | 147 | 152 | 186 | 154 | 172 | 166 | 225 | 177 |
| Other Income | 0 | 1 | 1 | 3 | -0 | 1 | 2 | 3 | 1 | 1 |
| Total Income | 144 | 132 | 148 | 155 | 186 | 155 | 174 | 170 | 226 | 178 |
| Total Expenditure | 118 | 108 | 119 | 122 | 146 | 120 | 148 | 140 | 182 | 147 |
| Operating Profit | 26 | 24 | 29 | 34 | 41 | 35 | 26 | 30 | 45 | 31 |
| Interest | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 3 | 2 | 4 |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 5 | 6 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | -32 | 0 | -0 | 0 |
| Profit Before Tax | 22 | 20 | 26 | 30 | 37 | 31 | -10 | 24 | 37 | 20 |
| Provision for Tax | 1 | 5 | 7 | 7 | 9 | 9 | 7 | 6 | 12 | 5 |
| Profit After Tax | 21 | 15 | 19 | 22 | 27 | 22 | -17 | 18 | 26 | 15 |
| Adjustments | 0 | -0 | 0 | 0 | 0 | -3 | -2 | -1 | -1 | -1 |
| Profit After Adjustments | 21 | 15 | 19 | 22 | 27 | 20 | -19 | 17 | 25 | 14 |
| Adjusted Earnings Per Share | 5.8 | 4.1 | 5.2 | 6.1 | 7.5 | 5.4 | -5.1 | 4.5 | 6.8 | 3.4 |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 154 | 160 | 188 | 239 | 240 | 341 | 520 | 617 | 717 | 740 |
| Other Income | 3 | 0 | 3 | 0 | 3 | 1 | 3 | 4 | 7 | 7 |
| Total Income | 157 | 160 | 191 | 239 | 242 | 342 | 523 | 621 | 725 | 748 |
| Total Expenditure | 136 | 137 | 158 | 196 | 199 | 260 | 415 | 494 | 589 | 617 |
| Operating Profit | 21 | 23 | 33 | 42 | 44 | 82 | 108 | 127 | 136 | 132 |
| Interest | 3 | 3 | 3 | 5 | 6 | 6 | 6 | 2 | 6 | 10 |
| Depreciation | 1 | 1 | 2 | 3 | 4 | 4 | 10 | 12 | 16 | 19 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -32 | -32 |
| Profit Before Tax | 18 | 19 | 28 | 35 | 35 | 72 | 91 | 112 | 82 | 71 |
| Provision for Tax | 5 | 7 | 10 | 12 | 7 | 18 | 20 | 29 | 33 | 30 |
| Profit After Tax | 13 | 12 | 18 | 23 | 27 | 54 | 72 | 83 | 49 | 42 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -6 | -5 |
| Profit After Adjustments | 13 | 12 | 19 | 23 | 27 | 54 | 72 | 83 | 43 | 37 |
| Adjusted Earnings Per Share | 4 | 3.8 | 5.9 | 7.4 | 8.7 | 5.7 | 19.7 | 22.9 | 11.6 | 9.6 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 16% | 28% | 25% | 0% |
| Operating Profit CAGR | 7% | 18% | 26% | 0% |
| PAT CAGR | -41% | -3% | 16% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 8% | NA% | NA% | NA% |
| ROE Average | 8% | 15% | 23% | 30% |
| ROCE Average | 12% | 19% | 23% | 29% |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 27 | 39 | 58 | 82 | 112 | 167 | 522 | 594 | 674 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9 |
| Borrowings | 16 | 15 | 32 | 22 | 20 | 73 | 1 | 1 | 114 |
| Other Non-Current Liabilities | -1 | 1 | 1 | 3 | 6 | 8 | 7 | 10 | 14 |
| Total Current Liabilities | 49 | 55 | 65 | 106 | 95 | 166 | 129 | 163 | 285 |
| Total Liabilities | 91 | 109 | 155 | 213 | 232 | 413 | 659 | 767 | 1096 |
| Fixed Assets | 18 | 28 | 32 | 79 | 85 | 186 | 205 | 259 | 427 |
| Other Non-Current Assets | 6 | 15 | 35 | 7 | 20 | 5 | 25 | 51 | 173 |
| Total Current Assets | 66 | 66 | 87 | 124 | 121 | 216 | 430 | 457 | 496 |
| Total Assets | 91 | 109 | 155 | 213 | 232 | 413 | 659 | 767 | 1096 |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 0 | 3 | 1 | 0 | 4 | 3 | 10 | 31 |
| Cash Flow from Operating Activities | 10 | 29 | 8 | 15 | 27 | 28 | -12 | 66 | 125 |
| Cash Flow from Investing Activities | -14 | -19 | -25 | -21 | -24 | -101 | -121 | -33 | -365 |
| Cash Flow from Financing Activities | 4 | -7 | 15 | 6 | 0 | 72 | 140 | -12 | 239 |
| Net Cash Inflow / Outflow | -0 | 3 | -2 | -0 | 3 | -1 | 8 | 20 | -1 |
| Closing Cash & Cash Equivalent | 0 | 3 | 1 | 0 | 4 | 3 | 10 | 31 | 30 |
| # | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 4.02 | 3.82 | 5.89 | 7.4 | 8.72 | 5.71 | 19.75 | 22.86 | 11.6 |
| CEPS(Rs) | 4.27 | 4.26 | 6.48 | 8.22 | 9.84 | 6.16 | 22.51 | 26.25 | 17.56 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 3 |
| Book NAV/Share(Rs) | 8.65 | 12.34 | 17.75 | 24.94 | 33.62 | 17.01 | 143.34 | 163.01 | 182.13 |
| Core EBITDA Margin(%) | 11.83 | 14.43 | 16.21 | 17.64 | 17.12 | 23.53 | 20.22 | 19.88 | 17.91 |
| EBIT Margin(%) | 13.18 | 13.71 | 16.77 | 16.71 | 16.83 | 22.71 | 18.81 | 18.58 | 12.24 |
| Pre Tax Margin(%) | 11.52 | 11.66 | 15.06 | 14.72 | 14.5 | 21.06 | 17.58 | 18.19 | 11.42 |
| PAT Margin (%) | 8.23 | 7.52 | 9.83 | 9.77 | 11.46 | 15.85 | 13.83 | 13.51 | 6.79 |
| Cash Profit Margin (%) | 8.75 | 8.37 | 10.84 | 10.86 | 12.93 | 17.08 | 15.77 | 15.51 | 9.03 |
| ROA(%) | 13.87 | 12.04 | 13.99 | 12.64 | 12.34 | 16.74 | 13.42 | 11.68 | 5.23 |
| ROE(%) | 46.43 | 36.44 | 39.03 | 34.64 | 29.78 | 40.51 | 21.07 | 14.92 | 7.7 |
| ROCE(%) | 35.54 | 35.91 | 38.24 | 34.33 | 27.09 | 33.43 | 23.85 | 20.45 | 11.81 |
| Receivable days | 86.2 | 82.89 | 83.83 | 96.45 | 100.9 | 94.89 | 99.79 | 116.58 | 111.06 |
| Inventory Days | 46.64 | 44.82 | 45.68 | 50.54 | 69.31 | 60.39 | 60.54 | 68.46 | 70.18 |
| Payable days | 113.37 | 128.43 | 139.26 | 142.81 | 169.65 | 138.36 | 135.92 | 143.66 | 122.64 |
| PER(x) | 0 | 0 | 0 | 0 | 0 | 0 | 50.63 | 38.89 | 94.36 |
| Price/Book(x) | 0 | 0 | 0 | 0 | 0 | 0 | 6.97 | 5.45 | 6.01 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 | 0.3 | 0.34 | 0.27 |
| EV/Net Sales(x) | 0.2 | 0.15 | 0.23 | 0.27 | 0.28 | 0.49 | 6.81 | 5.16 | 5.85 |
| EV/Core EBITDA(x) | 1.46 | 1.05 | 1.32 | 1.51 | 1.51 | 2.03 | 32.83 | 25.09 | 30.88 |
| Net Sales Growth(%) | 0 | 4.27 | 17.45 | 26.72 | 0.47 | 42.13 | 52.71 | 18.57 | 16.33 |
| EBIT Growth(%) | 0 | 8.48 | 43.65 | 26.26 | 1.2 | 91.73 | 26.52 | 17.09 | -23.34 |
| PAT Growth(%) | 0 | -4.8 | 53.51 | 25.95 | 17.92 | 96.57 | 33.24 | 15.77 | -41.52 |
| EPS Growth(%) | 0 | -4.8 | 54.05 | 25.51 | 17.92 | -34.47 | 245.55 | 15.77 | -49.26 |
| Debt/Equity(x) | 1.09 | 0.68 | 0.78 | 0.69 | 0.56 | 0.85 | 0 | 0.01 | 0.32 |
| Current Ratio(x) | 1.36 | 1.21 | 1.34 | 1.18 | 1.28 | 1.3 | 3.32 | 2.81 | 1.74 |
| Quick Ratio(x) | 0.96 | 0.85 | 0.92 | 0.81 | 0.73 | 0.94 | 2.45 | 2.08 | 1.19 |
| Interest Cover(x) | 7.92 | 6.67 | 9.79 | 8.39 | 7.22 | 13.77 | 15.27 | 47.5 | 14.79 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.05 |
| # | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | May 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 41.05 | 39.41 | 39.41 | 39.41 | 39.41 | 38.93 | 39.91 | 39.91 | 39.07 | 35.98 |
| FII | 1.84 | 5.76 | 6.41 | 6.36 | 6.73 | 7.16 | 11.65 | 8.97 | 10.01 | 12.92 |
| DII | 4.19 | 3.61 | 3.72 | 3.63 | 5.12 | 5.94 | 7.58 | 6.81 | 8.81 | 14.81 |
| Public | 52.91 | 51.22 | 50.46 | 50.6 | 48.74 | 47.97 | 40.86 | 44.31 | 42.12 | 36.29 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | May 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 1.5 | 1.44 | 1.44 | 1.44 | 1.44 | 1.44 | 1.47 | 1.47 | 1.47 | 1.47 |
| FII | 0.07 | 0.21 | 0.23 | 0.23 | 0.25 | 0.26 | 0.43 | 0.33 | 0.38 | 0.53 |
| DII | 0.15 | 0.13 | 0.14 | 0.13 | 0.19 | 0.22 | 0.28 | 0.25 | 0.33 | 0.61 |
| Public | 1.93 | 1.87 | 1.84 | 1.84 | 1.78 | 1.77 | 1.51 | 1.63 | 1.59 | 1.48 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3.64 | 3.64 | 3.64 | 3.64 | 3.64 | 3.69 | 3.69 | 3.69 | 3.77 | 4.09 |
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
You May Also Know About
